After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
A competitor to Mylan's MYL autoinjector, EpiPen, will hit the market sooner than expected thanks to a private pharmaceutical company, Kaleo Pharmaceuticals.
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
The likely continuation of a split government should help the sector recover from its recent beat-down.
Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.